BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Tempus AI Shares Slide Despite FDA Approval for xT CDx Cancer Test
Tempus AI Shares Slide Despite FDA Approval for xT CDx Cancer Test
0
BTCCSquare news:
Tempus AI's stock fell 1.66% to $50.44 despite securing FDA clearance for its tumor-only xT CDx genomic profiling test. The decline marked a sharp reversal from an early session high near $55, as initial investor enthusiasm faded by late morning trading.
The regulatory approval expands Tempus' cancer testing capabilities in solid tumors using next-generation sequencing. However, the market reaction underscores the disconnect between regulatory milestones and short-term price action in precision medicine stocks.
As a Nasdaq-listed company trading under ticker TEM, Tempus specializes in AI-driven diagnostic tools. The selloff occurred despite the test's potential to streamline oncology treatment decisions through tumor-only analysis.
By:
Log in to Reply
Log in to comment your thoughtsComments
Related Articles
|Square
Get the BTCC app to start your crypto journey
Get started today Scan to join our 100M+ users